Solid earnings beat with broad-based growth in Oncology and Rare Disease offsets CVRM weakness. The CSPC obesity deal adds long-term pipeline optionality but near-term R&D spend will increase. Guidance reaffirmation supports current valuation. Watch for H1 2026 results on 27 July 2026 and upcoming Phase III readouts for Enhertu (DESTINY-Breast05) and Calquence (AMPLIFY).
Price Chart
Executive Summary
AstraZeneca reported strong Q1 2026 results with Total Revenue up 8% CER to $15.3B, driven by Oncology (+16% CER) and Rare Disease (+15% CER). Core EPS grew 5% CER to $2.58, and FY 2026 guidance for mid-to-high single-digit revenue growth and low double-digit Core EPS growth was reaffirmed. The company also closed a $1.2B upfront collaboration with CSPC for obesity/diabetes therapies and reported positive Phase III readouts for tozorakimab and efzimfotase alfa.
Key Facts
- Total Revenue $15,288M, up 8% CER (actual +13%)
- Reported EPS $1.99, up 8% CER; Core EPS $2.58, up 5% CER
- Oncology revenue +16% CER, Rare Disease +15% CER
- CVRM revenue declined 6% CER, primarily due to Farxiga generic competition
- FY 2026 guidance reaffirmed: mid-to-high single-digit revenue growth, low double-digit Core EPS growth
- Closed $1.2B upfront collaboration with CSPC for obesity/type 2 diabetes therapies
- Positive Phase III data for tozorakimab (COPD) and efzimfotase alfa (HPP); Enhertu patent litigation resolved favorably
- Net debt increased to $25.9B, driven by financing activities and business development payments
Financial Impact
Q1 2026 revenue $15.3B, operating profit $4.2B (reported) and $5.4B (core); Core EPS $2.58, up 5% CER; $1.2B upfront for CSPC deal and $100M for Jacobio
Risk Factors
- Generic competition pressuring CVRM revenue, especially Farxiga and Brilinta
- Increased leverage from $1.2B CSPC upfront and $1.99B new debt issuance
- Litigation overhang from 340B antitrust appeal and Texas qui tam trial scheduled for August 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-004047 |
| Document: 0001654954-26-004047-index-headers.html | 0001654954-26-004047 |
| Document: 0001654954-26-004047-index.html | 0001654954-26-004047 |
| Document: 0001654954-26-004047.txt | 0001654954-26-004047 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $156.97 (−3.02%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $156.97 (+4.16%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $156.97 (−1.92%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.97 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.97 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.97 (−3.39%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.97 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.97 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.97 (−3.39%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $156.97 (+3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access